Table 1.
Baseline Characteristics of the Study Population
| UC (n = 93) | Inflammation Above Endoscopic Margin (%) | No Inflammation Above Endoscopic Margin (%) | |
|---|---|---|---|
| Male (%) | 51 (54.8) | 36 (69) | 16 (31) |
| Age at study inclusion, y, median (range) | 44 (17-88) | 43 (17-88) | 40 (19-75) |
| Disease extent, n (%) | |||
| Proctitis (E1) | 61 (65.6) | 45 (74) | 16 (26) |
| Left-sided colitis (E2) | 32 (34.4) | 21 (66) | 11 (34) |
| Clinical disease activity, n (%) | |||
| Mild | 65 (70) | 43 (65) | 22 (35) |
| Moderate | 27 (29) | 23 (85) | 4 (15) |
| Severe | 1 (1) | 1 (100) | 0 (0) |
| Endoscopic disease activity at baseline, n (%) | |||
| Mayo endoscopic score 1 | 35 (37.9) | 29 (83) | 6 (17) |
| Mayo endoscopic score 2 | 44 (47.8) | 27 (61) | 17 (39) |
| Mayo endoscopic score 3 | 14 (15.2) | 10 (71) | 4 (29) |
| Medication use at baseline | |||
| Topical 5-ASA | 78 (84) | 58 (74) | 20 (26) |
| Oral 5-ASA | 56 (60) | 39 (85) | 17 (15) |
| Thiopurines | 2 (2.2) | 2 (100) | 0 (0) |
| Biologics | 1 (1.1) | 1 (100) | 0 (0) |
| Outcomes during follow-up, n (%) | |||
| Steroids | 20 (21.5) | 17 (85) | 3 (15) |
| Hospitalization | 12 (12.9) | 10 (83) | 2 (13) |
| Therapy escalation | 15 (16.1) | 11 (73) | 4 (27) |
| Proximal extension | 15 (16.1) | 13 (87) | 2 (13) |
| ASUC | 5 (5.4) | 5 (100) | 0 (0) |
| Colectomy | 1 (1.1) | 1 (100) | 0 (0) |
ASUC indicates acute severe ulcerative colitis; 5-ASA, aminosalicylates.